Fitaro 0.25 mg/0.5 ml (SC Injection)
0.25 mg pre-filled syringe: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Semaglutide |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Adjunct to diet and exercise for type 2 diabetes mellitus
- Reduction of risk of major adverse cardiovascular events in type 2 diabetes mellitus patients
- Chronic weight management for obesity patients
Pharmacology
- GLP-1 analog with 94% sequence similarity to human GLP-1
- Reduces blood glucose in a glucose dependent manner
- Stimulates insulin secretion and lowers glucagon secretion
- Reduces body weight and body fat mass by reducing appetite
Dosage & Administration
- Starter dose of 3 mg once daily for 30 days
- Maintenance dose of 7 mg once daily
- Additional glycemic control with 14 mg once daily (for diabetes)
- Semaglutide injection starting dose of 0.25 mg once weekly for diabetes
- Injection site: abdomen, thigh, or upper arm
- Semaglutide injection for obesity starting with 0.25 mg once weekly for 4 weeks
Interaction
- Delays gastric emptying
- Potential impact on absorption of concomitantly administered oral medicinal products
Contraindications
- Hypersensitivity to active substance or excipients
Side Effects
- Hypoglycemia when used with insulin or sulfonylurea
- Gastrointestinal disorders
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Constipation
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
Pregnancy & Lactation
- Not to be used during pregnancy
- Discontinue at least 2 months before planned pregnancy
- Not to be used during breastfeeding
Precautions & Warnings
- Not for type 1 diabetes mellitus or treatment of diabetic ketoacidosis
- Discontinue promptly if pancreatitis suspected
- Monitoring for patients with diabetic retinopathy
Use in Special Populations
- Not established for children and adolescents below 18 years
- No dose adjustment based on age
- No dose adjustment for mild, moderate, or severe renal impairment
- Not recommended for end-stage renal disease
- No dose adjustment for hepatic impairment
- Caution for treating patients with hepatic impairment
Overdose Effects
- Reported overdose of up to 4 mg in a single dose and up to 4 mg in a week
- Most common adverse reaction: nausea
- No specific antidote
- Supportive treatment based on clinical signs and symptoms
- Consider dose reduction of sulfonylurea or insulin to reduce hypoglycemia risk
Therapeutic Class
- GLP-1 receptor agonists
Storage Conditions
- Store at 2°C to 8°C (in a refrigerator)
- Do not freeze
- Keep out of reach of children